OPEN MARKET SALES AGREEMENTSMOpen Market Sales Agreement • January 19th, 2024 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO OPEN MARKET SALE AGREEMENTSMOpen Market Sales Agreement • October 3rd, 2022 • Calyxt, Inc. • Agricultural chemicals • New York
Reference is made to the Open Market Sales Agreement, dated September 21, 2021 (the “Agreement”), by and between Calyxt, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”). The Company and the Agent (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 8(h) of the Agreement, to remove the aggregate offering price cap under the Agreement (this “Amendment”). The Parties therefore hereby agree as follows:
AMENDMENT NO. 1 TO THE OPEN MARKET SALES AGREEMENTOpen Market Sales Agreement • August 7th, 2019 • ObsEva SA • Pharmaceutical preparations • New York
This Amendment No. 1 to the Open Market Sales Agreement (this “Amendment”) is entered into as of the date first written above by ObsEva SA, a société anonyme organized under the laws of Switzerland (the “Company”), and Jefferies LLC (“Agent”), that are parties to that certain Open Market Sales Agreement dated March 16, 2018 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:
